UBS raises Viatris stock price target on cenerimod outlook By Investing.com

UBS has increased its price target for Viatris Inc. (NASDAQ:VTRS) to $26.00 from $23.00, maintaining a Buy rating, citing growth drivers like Chinese operations, hormone replacement therapy, and upcoming OPUS readouts, with a particular focus on the underappreciated cenerimod Phase 3 readout. Despite a 40% year-to-date gain and trading near its 52-week high, UBS believes the stock remains undervalued. The new price target is based on a higher 9.0x price-to-earnings multiple due to an improved ou